MODERNA, INC. |
Market Closed -
Other stock markets
|
Pre-market 04:03:34 am | |||
| 125.6 USD | +12.68% |
|
123.4 | -1.74% |
| 02/05 | Equity Markets Close Higher Ahead of Jobs Report | MT |
| 02/05 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
06/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
111.5
USD
Average target price
135.3
USD
Spread / Average Target
+21.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.28% | 42.68B | |
| -3.99% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +6.36% | 24.94B | |
| -21.47% | 18.96B | |
| +27.58% | 12.3B | |
| -2.75% | 11.95B | |
| -2.02% | 11.55B | |
| +17.39% | 11.32B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Sector Update: Health Care Stocks Still Looking for Direction This Afternoon
